Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities.
Autoimmune rheumatic diseases
Endothelial dysfunction
Microvesicles
Thromboinflammation
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
21
06
2021
pubmed:
6
7
2021
medline:
7
4
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
Cardiovascular risk is increased in patients with autoimmune rheumatic diseases. Endothelial, erythrocyte and platelet microvesicles (MVs) are elevated in patients with cardiovascular diseases and represent novel markers of endothelial dysfunction and thromboinflammation. We tested whether their levels are increased in patients with autoimmune rheumatic diseases (ARDs) in the absence of disease flare and cardiovascular comorbidities. Well-controlled patients with rheumatoid arthritis or systemic lupus erythematosus were studied, provided they were free from cardiovascular comorbidities and established cardiovascular disease. We additionally studied (a) a control group consisting of healthy volunteers and (b) a reference group including patients with stable coronary artery disease (CAD). MVs were measured using a standardized flow cytometry protocol. In a population of 74 participants, patients with ARDs (n = 17) presented increased levels of both endothelial (283.3 ± 195.0/μL vs 168.5 ± 54.8/μL, p = 0.029) and platelet MVs (374.0 ± 275.3/μL vs 225.7 ± 101.1/μL, p = 0.046) compared to controls (n = 34), whereas erythrocyte MVs did not significantly differ. In addition, patients with ARDs showed similar levels of endothelial MVs compared to CAD patients (n = 23) (283.3 ± 195.0/μL vs 297.0 ± 211.8/μL, p = 0.846). Platelet MVs were significantly associated with disease duration, and erythrocyte MVs with patients' perceived disease activity. In conclusion, increased levels of endothelial and platelet MVs may be evident in patients with ARDs, even in the absence of disease flares and before the establishment of cardiovascular complications. Levels of endothelial MVs resemble those of patients with profound atherothrombotic profile. The prognostic potential of MVs in terms of cardiovascular disease prevention warrants further investigation in patients with ARDs.
Identifiants
pubmed: 34224067
doi: 10.1007/s11239-021-02517-0
pii: 10.1007/s11239-021-02517-0
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-16Subventions
Organisme : European Social Fund
ID : MIS 5047870
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E (2020) Endothelial dysfunction in patients with rheumatoid arthritis: the role of hypertension. Curr Hypertens Rep 22:56
doi: 10.1007/s11906-020-01064-y
Anyfanti P, Triantafyllou A, Gkaliagkousi E et al (2017) Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors. Clin Rheumatol 36:1229–1236. https://doi.org/10.1007/s10067-017-3659-9
doi: 10.1007/s10067-017-3659-9
pubmed: 28455826
Anyfanti P, Triantafyllou A, Gkaliagkousi E et al (2017) Retinal vessel morphology in rheumatoid arthritis: association with systemic inflammation, subclinical atherosclerosis and cardiovascular risk. Microcirculation. https://doi.org/10.1111/micc.12417
doi: 10.1111/micc.12417
pubmed: 28926162
Anyfanti P, Gkaliagkousi E, Triantafyllou A et al (2018) Dermal capillary rarefaction as a marker of microvascular damage in patients with rheumatoid arthritis: association with inflammation and disorders of the macrocirculation. Microcirculation 25:e12451. https://doi.org/10.1111/micc.12451
doi: 10.1111/micc.12451
pubmed: 29734516
Koletsos N, Gkaliagkousi E, Lazaridis A et al (2021) Skin microvascular dysfunction in patients with systemic lupus erythematosus with and without cardiovascular risk factors. Rheumatology 60:2834–2841. https://doi.org/10.1093/rheumatology/keaa722
Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S (2015) Clinical significance of endothelial dysfunction in essential hypertension. Curr Hypertens Rep. https://doi.org/10.1007/s11906-015-0596-3
doi: 10.1007/s11906-015-0596-3
pubmed: 26371063
Van Es N, Bleker S, Sturk A, Nieuwland R (2015) Clinical significance of tissue factor-exposing microparticles in arterial and venous thrombosis. Semin Thromb Hemost 41:718–727. https://doi.org/10.1055/s-0035-1556047
doi: 10.1055/s-0035-1556047
pubmed: 26408926
Lipets EN, Antonova OA, Shustova ON et al (2020) Use of Thrombodynamics for revealing the participation of platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation. PLoS One 15:e0227932. https://doi.org/10.1371/journal.pone.0227932
doi: 10.1371/journal.pone.0227932
pubmed: 32469873
pmcid: 7259734
Gkaliagkousi E, Gavriilaki E, Vasileiadis I et al (2019) Endothelial microvesicles circulating in peripheral and coronary circulation are associated with central blood pressure in coronary artery disease. Am J Hypertens 32:1199–1205. https://doi.org/10.1093/ajh/hpz116
doi: 10.1093/ajh/hpz116
pubmed: 31350539
Gkaliagkousi E, Nikolaidou B, Gavriilaki E et al (2019) Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. Diabetes Vasc Dis Res 16:458–465. https://doi.org/10.1177/1479164119844691
doi: 10.1177/1479164119844691
Gkaliagkousi E, Gavriilaki E, Yiannaki E et al (2021) Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02302-5
doi: 10.1007/s11239-020-02302-5
pubmed: 34224067
Ridger VC, Boulanger CM, Angelillo-Scherrer A et al (2017) Microvesicles in vascular homeostasis and diseases. Thromb Haemost 117:1296–1316. https://doi.org/10.1160/th16-12-0943
doi: 10.1160/th16-12-0943
pubmed: 28569921
Bruce B, Fries JF (2005) The health assessment questionnaire (HAQ). Clin Exp Rheumatol 23(5 Suppl 39):S14-8
World Medical Association (2013) World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194. https://doi.org/10.1001/jama.2013.281053
Bordy R, Totoson P, Prati C et al (2018) Microvascular endothelial dysfunction in rheumatoid arthritis. Nat Rev Rheumatol 14:404–420. https://doi.org/10.1038/s41584-018-0022-8
doi: 10.1038/s41584-018-0022-8
pubmed: 29855620
Frangou E, Chrysanthopoulou A, Mitsios A et al (2019) REDD1_autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE). Ann Rheum Dis 78:238–248
doi: 10.1136/annrheumdis-2018-213181
Kambas K, Chrysanthopoulou A, Vassilopoulos D et al (2013) Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 73:1854–1863
doi: 10.1136/annrheumdis-2013-203430
Rodríguez-Carrio J, Alperi-López M, López P et al (2015) Altered profile of circulating microparticles in rheumatoid arthritis patients. Clin Sci 128:437–448. https://doi.org/10.1042/CS20140675
doi: 10.1042/CS20140675
Pamuk GE, Vural Ö, Turgut B et al (2008) Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets 19:146–154. https://doi.org/10.1080/09537100701210057
doi: 10.1080/09537100701210057
pubmed: 17852775
Gitz E, Pollitt AY, Gitz-francois JJ et al (2016) CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 124:2262–2271. https://doi.org/10.1182/blood-2014-05-572818.The
doi: 10.1182/blood-2014-05-572818.The
Knijff-Dutmer EAJ, Koerts J, Nieuwland R et al (2002) Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46:1498–1503. https://doi.org/10.1002/art.10312
doi: 10.1002/art.10312
pubmed: 12115179
Pereira J, Alfaro G, Goycoolea M et al (2006) Circulating platelet-derived microparticles in systemic lupus erythematosus. Thromb Haemost 95:94–99. https://doi.org/10.1160/th05-05-0310
doi: 10.1160/th05-05-0310
pubmed: 16543967
Sellam J, Proulle V, Jüngel A et al (2009) Increased levels of circulating microparticles in primary Sjögren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 11:1–11. https://doi.org/10.1186/ar2833
doi: 10.1186/ar2833
Nielsen CT, Østergaard O, Johnsen C et al (2011) Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum 63:3067–3077. https://doi.org/10.1002/art.30499
doi: 10.1002/art.30499
pubmed: 21702008
Erdbruegger U, Grossheim M, Hertel B et al (2008) Diagnostic role of endothelial microparticles in vasculitis. Rheumatology 47:1820–1825. https://doi.org/10.1093/rheumatology/ken373
doi: 10.1093/rheumatology/ken373
pubmed: 18927191
Brogan PA, Shah V, Brachet C et al (2004) Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 50:927–936. https://doi.org/10.1002/art.20199
doi: 10.1002/art.20199
pubmed: 15022336
Bartoloni E, Alunno A, Bistoni O et al (2015) Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren’s syndrome: new markers of chronic endothelial damage? Rheumatol (United Kingdom) 54:536–544. https://doi.org/10.1093/rheumatology/keu320
doi: 10.1093/rheumatology/keu320
López P, Rodríguez-Carrio J, Martínez-Zapico A et al (2017) Circulating microparticle subpopulations in systemic lupus erythematosus are affected by disease activity. Int J Cardiol 236:138–144. https://doi.org/10.1016/j.ijcard.2017.02.107
doi: 10.1016/j.ijcard.2017.02.107
pubmed: 28279502